Reuters
Acomplia, or rimonabant, is tipped by analysts as a future multibillion-dollar-a-year seller, since it can help people both lose weight and quit smoking.
Until now, however, it had been uncertain how comprehensive the next set of clinical results would be. The decision to publish two-year figures was taken by industry analysts as a sign the product was progressing well in tests.
More... |